MA44557B1 - Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer - Google Patents

Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer

Info

Publication number
MA44557B1
MA44557B1 MA44557A MA44557A MA44557B1 MA 44557 B1 MA44557 B1 MA 44557B1 MA 44557 A MA44557 A MA 44557A MA 44557 A MA44557 A MA 44557A MA 44557 B1 MA44557 B1 MA 44557B1
Authority
MA
Morocco
Prior art keywords
vaccine
buffer
stable
acid
low
Prior art date
Application number
MA44557A
Other languages
English (en)
Other versions
MA44557A1 (fr
Inventor
Krishna Mohan Vadrevu
Sai Devarajulu Prasad
Krishna Murthy Ella
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of MA44557A1 publication Critical patent/MA44557A1/fr
Publication of MA44557B1 publication Critical patent/MA44557B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

L'invention concerne un vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer. Le vaccin est disponible sous la forme de doses d'un volume inférieur à 1 ml par dose destinées à être administrées par voie orale, et ne contient pas de tampon. Le vaccin ne nécessite pas d'administration, avant ou après l'administration par voie orale du vaccin au patient, d'anti-acide qui viserait à neutraliser l'acidité gastrique. Le vaccin montre une diminution de la ch
MA44557A 2016-06-16 2017-06-12 Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer MA44557B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641020675 2016-06-16
PCT/IN2017/050237 WO2017216808A1 (fr) 2016-06-16 2017-06-13 Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer

Publications (2)

Publication Number Publication Date
MA44557A1 MA44557A1 (fr) 2020-01-31
MA44557B1 true MA44557B1 (fr) 2021-11-30

Family

ID=60664101

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44557A MA44557B1 (fr) 2016-06-16 2017-06-12 Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer

Country Status (22)

Country Link
US (1) US11351245B2 (fr)
EP (1) EP3471768A4 (fr)
JP (1) JP7108549B2 (fr)
KR (3) KR20230125863A (fr)
CN (1) CN109562159B (fr)
AU (1) AU2017285408B2 (fr)
BR (1) BR112018076094A2 (fr)
CA (1) CA3027703A1 (fr)
CO (1) CO2019000078A2 (fr)
EA (1) EA201990027A1 (fr)
GB (1) GB2566244B (fr)
IL (1) IL263740B2 (fr)
JO (1) JOP20180124A1 (fr)
MA (1) MA44557B1 (fr)
MX (1) MX2018015469A (fr)
MY (1) MY198419A (fr)
PH (1) PH12018502650A1 (fr)
SG (2) SG11201811188TA (fr)
TN (1) TN2018000436A1 (fr)
UA (1) UA124430C2 (fr)
WO (1) WO2017216808A1 (fr)
ZA (1) ZA201900176B (fr)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
EP0939648B1 (fr) 1996-09-26 2007-11-07 Merck & Co., Inc. Formulations de vaccins a rotavirus
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
ID20581A (id) * 1996-10-18 1999-01-21 Res Fnd For Micbial Diseases O Antigen rotavirus, vaksin dan agen diagnostik untuk infeksi rotavirus, serta metode untuk menghasilkan antigen
KR100688434B1 (ko) 1998-07-28 2007-03-09 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 다가의 인간-소의 로타바이러스 백신
DE122006000026I1 (de) 1999-08-17 2006-10-12 Glaxosmithkline Biolog Sa Methoden um Rotavirusvarianten zu trennen und lebender attenuierter Rotavirus impfstoff
JP2005038411A (ja) 2003-06-30 2005-02-10 Sony Corp 機器認証情報組込システム、端末機器、機器認証情報処理方法、機器認証情報処理プログラム、提供サーバ、機器認証情報提供方法、機器認証情報提供プログラム、及び記憶媒体
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0516944D0 (en) * 2005-08-17 2005-09-28 Glaxosmithkline Biolog Sa Vaccine
GB2451216B (en) 2006-05-12 2011-05-04 Bharat Biotech Int Ltd A stabilised vaccine composition comprising a viral antigen, HSA and a hydrolysed protein
CN101638638A (zh) * 2008-07-29 2010-02-03 辽宁依生生物制药有限公司 人猪重配轮状病毒
CN102470170B (zh) 2009-07-13 2015-03-18 巴拉特生物技术国际有限公司 用作轮状病毒疫苗的组合物及其方法
JP2014512410A (ja) * 2011-04-28 2014-05-22 インターナショナル メディカ ファウンデーション 液体ワクチン調製物
RU2643929C2 (ru) * 2012-04-23 2018-02-06 Бхарат Байотек Интернэшнл Лимитед Новые ротавирусные вакцинные композиции и способ получения вышеуказанных композиций

Also Published As

Publication number Publication date
KR20230125863A (ko) 2023-08-29
SG11201811188TA (en) 2019-01-30
US20190142932A1 (en) 2019-05-16
KR20190020046A (ko) 2019-02-27
EA201990027A1 (ru) 2019-07-31
CN109562159A (zh) 2019-04-02
PH12018502650A1 (en) 2019-10-07
GB2566244A (en) 2019-03-06
CA3027703A1 (fr) 2017-12-21
IL263740B1 (en) 2023-09-01
AU2017285408A1 (en) 2019-01-31
IL263740B2 (en) 2024-01-01
JP2019518056A (ja) 2019-06-27
GB201900562D0 (en) 2019-03-06
US11351245B2 (en) 2022-06-07
MY198419A (en) 2023-08-29
MX2018015469A (es) 2019-04-24
SG10202012281TA (en) 2021-01-28
UA124430C2 (uk) 2021-09-15
BR112018076094A2 (pt) 2019-03-26
CN109562159B (zh) 2022-10-28
JOP20180124A1 (ar) 2019-01-30
EP3471768A1 (fr) 2019-04-24
KR20220063302A (ko) 2022-05-17
GB2566244B (en) 2021-10-13
TN2018000436A1 (en) 2020-06-15
MA44557A1 (fr) 2020-01-31
AU2017285408B2 (en) 2024-05-02
EP3471768A4 (fr) 2020-03-04
IL263740A (en) 2019-01-31
ZA201900176B (en) 2019-09-25
CO2019000078A2 (es) 2019-01-18
WO2017216808A1 (fr) 2017-12-21
JP7108549B2 (ja) 2022-07-28

Similar Documents

Publication Publication Date Title
EA201790568A1 (ru) Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
EP4233892A3 (fr) Formulation stable anti-ifnar1
CL2017003320A1 (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
CA3030422C (fr) Excipients stabilisants pour formulations de proteines therapeutiques
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
RU2017134443A (ru) Способ лечения с применением традипитанта
EA201792591A1 (ru) Фармацевтические препараты
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
WO2018091729A3 (fr) Formulations pharmaceutiques aqueuses
EP4257149A3 (fr) Formulation liquide stable de gonadotrophines
CY1124635T1 (el) Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
JP2016534062A5 (fr)
EA201792144A1 (ru) Стабильный препарат для парентерального введения тапентадола
JP2018506533A5 (fr)
MA44557B1 (fr) Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
EA201990668A1 (ru) Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
WO2014193269A3 (fr) Médicament à base de diindolylméthane et son utilisation pour traiter la grippe et les infections virales respiratoires
FI3137094T3 (fi) Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
CY1120282T1 (el) Φαρμακευτικη συνθεση κιτρικης σιλδεναφιλης με την μορφη ενος εναιωρηματος για εκ του στοματος χρηση
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf